RESEARCH ARTICLE


Efficacy and Safety of an Intracameral Combination of Two Mydriatics and an Anesthetic for Phacoemulsification in Complicated Patients



Raffaele Nuzzi1, *, Valentina Baratozzi2, Maria Sole Polito1, Federico Tridico1
1 Institute of Ophthalmology, Department of Surgical Sciences, University of Turin, Corso Dogliotti, 14 10126, Turin, Italy
2 S. Luigi Gonzaga University Hospital, Regione Gonzole 10, 10043, Orbassano, Turin, Italy


Article Metrics

CrossRef Citations:
5
Total Statistics:

Full-Text HTML Views: 3351
Abstract HTML Views: 1546
PDF Downloads: 750
ePub Downloads: 631
Total Views/Downloads: 6278
Unique Statistics:

Full-Text HTML Views: 1897
Abstract HTML Views: 958
PDF Downloads: 509
ePub Downloads: 407
Total Views/Downloads: 3771



Creative Commons License
© 2018 Nuzzi et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Surgical Sciences, University of Turin, Corso Dogliotti, 14 10126, Turin, Italy; Tel: +39368203493; E-mail: prof.nuzzi_raffaele@hotmail.it


Abstract

Background:

Advantages of intracameral mydriatics have been demonstrated in healthy patients, but safety and efficacy in complicated subjects remain to be assessed.

Objective:

The purpose of this study is to evaluate efficacy and safety of an intracameral combination of phenylephrine (0.31%), tropicamide (0.02%) and lidocaine (1%) (Mydrane®, Thea Inc.) in phacoemulsification surgery in subgroups of patients affected by different systemic and ocular diseases.

Methods:

125 patients were recruited and compared with a control group of 39 patients. Both groups have been divided according to the presence/absence of ocular or systemic diseases. In course of surgery, grade of mydriasis and ocular analgesia have been evaluated by the surgeon. During follow-up, eventual adverse events have been monitored. Also, comfort reported by patients and surgeon has been investigated.

Results:

99.2% of patients receiving the intracameral formulation achieved acceptable mydriasis (> 6 mm), maintained during capsulorhexis, phacoemulsification and IOL insertion without the need of additional mydriatics. No adverse events or sings of unsuccessful surgery were observed among treated patients.

Conclusion:

An intracameral mydriatic solution can be a safe and comfortable tool for inducing and maintaining intraoperative mydriasis and analgesia, even in complicated patients.

Keywords: Cataract surgery, Corneal dystrophy, Diabetes, Glaucoma, Intracameral mydriatic, Ocular comorbidities, Systemic diseases.